Pfizer eyes up ‘significant opportunity’ for pentavalent meningococcal vaccine following positive top-line results from Phase 3 trial
Pfizer will submit a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine (MenABCWY) to the US Food and Drug Administration (FDA) later this year, following positive top-line results from a Phase 3 trial.
